Last update 04 Nov 2024

Valsartan

Overview

Basic Info

SummaryValsartan, a diminutive molecular compound, falls within the pharmacological group of angiotensin receptor blockers (ARBs), which exhibit the ability to selectively obstruct the angiotensin receptor type 1 (AR1R), hence deterring the effects of angiotensin II on the blood vessels, and consequently regulating the blood pressure. It is noteworthy that Valsartan is primarily intended to treat hypertension, heart failure, and myocardial infarction, with its debut approval by the FDA dating back to December 1996, all thanks to the efforts of Novartis in developing it. Valsartan has become widely recognized and hailed as a vital drug in the management of cardiovascular diseases, which serves as a testament to its efficacy and utility.
Drug Type
Small molecule drug
Synonyms
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine, Diovane, Kalpress
+ [24]
Target
Mechanism
AT1R antagonists(Angiotensin II Receptor Type 1 antagonists)
Therapeutic Areas
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (23 Dec 1996),
Regulation-
Login to view timeline

Structure

Molecular FormulaC24H29N5O3
InChIKeyACWBQPMHZXGDFX-QFIPXVFZSA-N
CAS Registry137862-53-4

External Link

KEGGWikiATCDrug Bank
D00400Valsartan

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ventricular Dysfunction, Left
US
19 Dec 2017
Myocardial Infarction
US
03 Aug 2005
Heart Failure
US
23 Dec 1996
Hypertension
US
23 Dec 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Kidney DiseasesPhase 3
US
01 Jun 2007
Chronic Kidney DiseasesPhase 3
BE
01 Jun 2007
Chronic Kidney DiseasesPhase 3
FR
01 Jun 2007
Chronic Kidney DiseasesPhase 3
DE
01 Jun 2007
Chronic Kidney DiseasesPhase 3
HU
01 Jun 2007
Chronic Kidney DiseasesPhase 3
IN
01 Jun 2007
Chronic Kidney DiseasesPhase 3
IT
01 Jun 2007
Chronic Kidney DiseasesPhase 3
PL
01 Jun 2007
Chronic Kidney DiseasesPhase 3
TR
01 Jun 2007
Hypertrophy, Left VentricularPhase 3
DE
01 Mar 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
30
ubhwzjdzxa(dfvoynekgp) = igfckhjwbq fksbvjgjgl (rukvtiolzx )
Positive
25 Aug 2023
Phase 3
93
(Sacubitril/Valsartan)
sfhhafjmik(awkufdetjg) = estqzzajtq pdrcfslcaa (nefnikgolk, intptbezbc - ayuijjnokw)
-
03 May 2023
(Valsartan)
sfhhafjmik(awkufdetjg) = ylvxehwdjo pdrcfslcaa (nefnikgolk, pcowccyktk - osgolgpsth)
Phase 3
5,661
sfewmbktea(qexfvcfztb): HR = 0.86 (95% CI, 0.74 - 0.99), P-Value = 0.04
Positive
02 Nov 2022
Not Applicable
Prediabetic State
TRG/ApoA-1 ratio | TRG/HDLC ratio
54
Valsartan/amlodipine 160/5mg
bocwrvysjw(vpxecltcia) = pvfkvlncew qkyupbqjtb (yjyvkpebzm )
-
07 Apr 2022
Phase 4
365
valsartan placebo+LCZ696
(LCZ696 (Entresto) + Placebo)
ebtdjhiqya(ntbtcjmlcy) = mfwinrglkn nifqtvmhne (ojcaekzels, waffnwwxhs - iwqejdidqk)
-
03 Dec 2021
LCZ696 placebo+valsartan
(Valsartan + Placebo)
ebtdjhiqya(ntbtcjmlcy) = qhjuypevsd nifqtvmhne (ojcaekzels, pjydjvuqwv - kpeosugzif)
Phase 2
178
oahgovtcgd(ieljhnffuv): P-Value = 0.001
Positive
01 Oct 2021
Placebo
Phase 3
127
aldjepfrce(lfzmpxnwlk) = srvgylqbkl pjdauxjlns (xkzgobnewv )
-
20 Sep 2021
aldjepfrce(lfzmpxnwlk) = ogmnxubqsf pjdauxjlns (xkzgobnewv )
Phase 3
66
jgekmtbfqq(wexdgnokbf) = zlrnjpqsuf jfnaiwehjx (zvablwyxmk, azzjnyjngq - vhflurxvwu)
-
20 May 2021
Phase 3
150
xtgsimjbpj(pglulywbop) = roocmwwebb ksvepkeioa (pxiqpkdvcb )
Positive
01 Mar 2019
(non-CKD)
xtgsimjbpj(pglulywbop) = bwwjepezjy ksvepkeioa (pxiqpkdvcb )
Not Applicable
Essential Hypertension
N-terminal pro-brain natriuretic peptide (NT-proBNP)
165
utnofassua(wujhppvteg) = zypbmhwaqp ovzteqxswj (bifsuemiyq )
-
27 Aug 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free